Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
2,325 questions in 216 reviews · Airways
current versionsNo studies 249 · 10.7%Ungraded 107 · 4.6%Very low 276 · 11.9%Low 751 · 32.3%Moderate 718 · 30.9%High 224 · 9.6%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Intervention NR Outcome№ of participants(studies) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR CFB in ACQ at 3 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 2450(3 RCTs) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 3 studies · 2450 participants | Moderate |
Intervention NR CFB in ACQ at 3 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 768(1 RCT) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 1 study · 3 participants | Low |
Intervention NR CFB in ACQ at 3 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 764(1 RCT) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 1 study · 3 participants | Low |
Intervention NR CFB in ACQ at 3 months ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants: 771(1 RCT) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 1 study · 3 participants | Low |
Intervention NR CFB in ACQ at 3 months ‐ HD TRIPLE vs HD‐ICS/LABA№ of participants: 767(1 RCT) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 1 study · 3 participants | Low |
Intervention NR MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator… Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR CFB in ACQ at 3 months ‐ HD TRIPLE vs MD TRIPLE№ of participants: 2079(2 RCTs) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 2 studies · 3 participants | Moderate |
Intervention NR CFB in ACQ at 3 months ‐ TRIPLE vs DUAL№ of participants: 1535(1 RCT) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 1 study · 3 participants | Moderate |
Intervention NR CFB in ACQ at 6 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 3762(3 RCTs) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 3 studies · 6 participants | Moderate |
Intervention NR CFB in ACQ at 6 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 1961(2 RCTs) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 2 studies · 6 participants | Moderate |
Intervention NR CFB in ACQ at 6 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 1952(2 RCTs) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 2 studies · 6 participants | Moderate |
Intervention NR CFB in ACQ at 6 months ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants: 2561(2 RCTs) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 2 studies · 6 participants | Moderate |
Intervention NR CFB in ACQ at 6 months ‐ HD TRIPLE vs HD‐ICS/LABA№ of participants: 3459(3 RCTs) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 3 studies · 6 participants | Low |
Intervention NR CFB in ACQ at 6 months ‐ HD TRIPLE vs MD TRIPLE№ of participants: 3288(3 RCTs) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 3 studies · 6 participants | Moderate |
Intervention NR CFB in ACQ at 6 months ‐ TRIPLE vs DUAL№ of participants: 5408(4 RCTs) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 4 studies · 6 participants | Moderate |
Intervention NR CFB in ACQ at 12 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 3152(3 RCTs) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 3 studies · 12 participants | Low |
Intervention NR Outcome№ of participants(studies) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR CFB in ACQ at 12 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 1366(2 RCTs) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 2 studies · 12 participants | Moderate |
Intervention NR CFB in ACQ at 12 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 1379(2 RCTs) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 2 studies · 12 participants | Moderate |
Intervention NR CFB in ACQ at 12 months ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants: 1967(2 RCTs) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 2 studies · 12 participants | Low |
Intervention NR CFB in ACQ at 12 months ‐ HD TRIPLE vs HD‐ICS/LABA№ of participants: 2887(3 RCTs) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 3 studies · 12 participants | Moderate |
Intervention NR CFB in ACQ at 12 months ‐ HD TRIPLE vs MD TRIPLE№ of participants: 1381(2 RCTs) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 2 studies · 12 participants | Moderate |
Intervention NR CFB in ACQ at 12 months ‐ DUAL vs TRIPLE№ of participants: 4253(4 RCTs) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 4 studies · 12 participants | Moderate |
Intervention NR Total studies: 4 RCTs Total Participants: 3454 · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator… Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 4 studies · 3454 participants | Ungraded |
Intervention NR HD‐ICS/LABA (Direct evidence; 1 RCT; 1223 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator… Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 1 study · 1223 participants | Moderate |
Intervention NR MD‐TRIPLE (Direct evidence; 0 RCTs; 0 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator… Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 0 studies · 0 participants | Low |
Intervention NR HD‐TRIPLE (Direct evidence; 0 RCTs; 0 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator… Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 0 studies · 0 participants | Low |
Intervention NR Severe exacerbations ‐ HD‐ICA/LABA vs MD‐ICS LABA№ of participants: 4492(5 RCTs) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | RR 1.49 [0.74, 3.01] | 5 studies · 4492 participants | Moderate |
Intervention NR MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator… Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | 1 | NR | Ungraded |
Intervention NR Total studies: 4 RCTs Total Participants: 4809 · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator… Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 4 studies · 4809 participants | Ungraded |
Intervention NR HD‐ICS/LABA (Direct evidence; 2 RCTs; 2815 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator… Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 2 studies · 2815 participants | Moderate |
Intervention NR MD‐TRIPLE (Direct evidence; 1 RCT; 1071 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator… Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 1 study · 1071 participants | Moderate |
Intervention NR HD‐TRIPLE (Direct evidence; 1 RCT; 1088 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator… Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 1 study · 1088 participants | Moderate |
Intervention NR MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator… Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | 1 | NR | Ungraded |
Intervention NR Outcome№ of participants(studies) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR CFB in AQLQ at 6 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 1223(1 RCT) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 1 study · 6 participants | Moderate |
Intervention NR CFB in AQLQ at 6 months ‐ HD TRIPLE vs HD‐ICS/LABA№ of participants: 907(2 RCTs) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 2 studies · 6 participants | Low |
Intervention NR CFB in AQLQ at 6 months ‐ HD TRIPLE vs MD TRIPLE№ of participants: 1426(1 RCT) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 1 study · 6 participants | Moderate |
Intervention NR Severe exacerbations ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 813(1 RCT) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | RR 1 [0.35, 2.83] | 1 study · 813 participants | Low |
Intervention NR CFB in AQLQ at 6 months ‐ TRIPLE vs DUAL№ of participants: 907(2 RCTs) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 2 studies · 6 participants | Low |
Intervention NR CFB in AQLQ at 12 months ‐ HD‐ICS/LABA vs MD‐ICS/LABA№ of participants: 2815(2 RCTs) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 2 studies · 12 participants | Moderate |
Intervention NR CFB in AQLQ at 12 months ‐ MD TRIPLE vs MD‐ICS/LABA№ of participants: 1071(1 RCT) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 1 study · 12 participants | Moderate |
Intervention NR CFB in AQLQ at 12 months ‐ HD TRIPLE vs MD‐ICS/LABA№ of participants: 1088(1 RCT) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 1 study · 12 participants | Moderate |
Intervention NR CFB in AQLQ at 12 months ‐ MD TRIPLE vs HD‐ICS/LABA№ of participants: 1628(1 RCT) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 1 study · 12 participants | Moderate |
Intervention NR CFB in AQLQ at 12 months ‐ HD TRIPLE vs HD‐ICS/LABA№ of participants: 2552(3 RCTs) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 3 studies · 12 participants | Moderate |
Intervention NR CFB in AQLQ at 12 months ‐ HD TRIPLE vs MD TRIPLE№ of participants: 1087(1 RCT) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 1 study · 12 participants | Moderate |
Intervention NR CFB in AQLQ at 12 months ‐ TRIPLE vs DUAL№ of participants: 3623(3 RCTs) Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 3 studies · 12 participants | Moderate |
Intervention NR Total studies: 7 RCTs Total Participants: 10453 · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator… Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 7 studies · 10453 participants | Ungraded |
Intervention NR HD‐ICS/LABA (Direct evidence; 3 RCTs; 3700 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator… Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and… (2022) · Cochrane | no estimate extracted | 3 studies · 3700 participants | Moderate |